Cargando…

Reduction of pericardial effusion in advanced non-small cell lung cancer patients with KRAS, TP53, and MET mutation treated with nivolumab

Nivolumab is an immune checkpoint inhibitor that is used to treat various advanced cancers, including metastatic non-small cell lung cancer (NSCLC). Nivolumab treatment has different side effects. For this patient with advanced NSCLC, pericardial effusion was considered to be an immune-related adver...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cai, Zhihui, Yao, Yuan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2020
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425282/ https://www.ncbi.nlm.nih.gov/pubmed/32780611 http://dx.doi.org/10.1177/0300060520937490

Ejemplares similares

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Pericardial effusion under nivolumab: case-reports and review of the literature
por: Anastasia, Saade, et al.
Publicado: (2019)

Correction to: Pericardial effusion under nivolumab: case-reports and review of the literature
por: Saade, Anastasia, et al.
Publicado: (2019)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature
por: Shaheen, Shagufta, et al.
Publicado: (2018)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

Efficacy of nivolumab in pre-treated non-small-cell lung cancer patients harbouring KRAS mutations
por: Passiglia, Francesco, et al.
Publicado: (2018)

Pericardial effusion
por: Marchiori, Edson, et al.
Publicado: (2021)

Survival Prediction of Patients Treated With Immune Checkpoint Inhibitors via KRAS/TP53/EGFR-Single Gene Mutation
por: Liu, Shui, et al.
Publicado: (2022)

TP53 missense mutation reveals gain-of-function properties in small-sized KRAS transformed pancreatic ductal adenocarcinoma
por: Zhou, Yiran, et al.
Publicado: (2023)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Pericardial Effusion With Tamponade in Lung Cancer Patients During Treatment With Nivolumab: A Report of Two Cases
por: Yamasaki, Masahiro, et al.
Publicado: (2019)

Late-onset Pleural and Pericardial Effusion as Immune-related Adverse Events after 94 Cycles of Nivolumab
por: Sawada, Ryo, et al.
Publicado: (2021)

On the Diagnosis of Pericardial Effusion
Publicado: (1926)

Large Pericardial Mass Mimicking Pericardial Effusion
por: Jayaprakash, Shilpa, et al.
Publicado: (2017)

PERICARDIAL EFFUSION AND TAMPONADE COMPLICATING TREATED GRAVES' THYROTOXOCOSIS
por: Teague, Emer, et al.
Publicado: (2009)

Correlation of MET gene amplification and TP53 mutation with PD-L1 expression in non-small cell lung cancer
por: Albitar, Maher, et al.
Publicado: (2018)

Atypical Presentation of Small Lymphocytic Lymphoma with Pericardial Effusion
por: Nnaoma, Christopher, et al.
Publicado: (2019)

Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
por: Fathi, Zahra, et al.
Publicado: (2018)

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
por: Du, Lijun, et al.
Publicado: (2017)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

Pericardial Tuberculoma: Transition from Asymptomatic Pericardial Effusion to Pericardial Mass
por: Lim, Kyunghee, et al.
Publicado: (2021)

Loss of TP53 cooperates with c-MET overexpression to drive hepatocarcinogenesis
por: Zhou, Yi, et al.
Publicado: (2023)

Cytokines in Pericardial Effusion of Patients with Inflammatory Pericardial Disease
por: Karatolios, Konstantinos, et al.
Publicado: (2012)

Case Report: Chemotherapy-free treatment with camrelizumab and anlotinib for elderly patients with KRAS and TP53 mutated advanced lung cancer
por: Qi, Wenbo, et al.
Publicado: (2023)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer
por: Ku, Bo Mi, et al.
Publicado: (2017)

Unusual presentation of pericardial effusion
por: Saseedharan, Sanjith, et al.
Publicado: (2012)

Unusual presentation of pericardial effusion
por: Muthialu, Nagarajan
Publicado: (2014)

Management of Malignant Pericardial Effusion
por: Petrofsky, Mary
Publicado: (2014)

Pericardial Effusion of Obscure Origin
por: Muralimohan, Ramya, et al.
Publicado: (2014)

Pericardial effusion: Real and false
por: Raut, Monish S., et al.
Publicado: (2015)

Pericardial Effusion in Celiac Disease
por: Ashrafi, Farzaneh, et al.
Publicado: (2014)

Pericardial Effusion-Associated Hyponatremia
por: Hanfy, Ahmed A., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ffjfa0b30dgu9vpjngmdu826re